BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22900896)

  • 1. Intralesional bevacizumab use for invasive ocular surface squamous neoplasia.
    Paul S; Stone DU
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):647-9. PubMed ID: 22900896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia.
    Rudkin AK; Muecke JS
    Br J Ophthalmol; 2011 Jul; 95(7):947-50. PubMed ID: 21252085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Ocular Surface Squamous Neoplasia with Topical and Intralesional Interferon Alpha 2B in Mexicans.
    Nava-Castañeda Á; Hernández-Orgaz J; Garnica-Hayashi L; Ansart A; Matus G; Tovilla-Canales JL
    Nepal J Ophthalmol; 2018 Jul; 10(20):143-150. PubMed ID: 31056557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subconjunctival bevacizumab injection for ocular surface squamous neoplasia.
    Faramarzi A; Feizi S
    Cornea; 2013 Jul; 32(7):998-1001. PubMed ID: 23538634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
    Sturges A; Butt AL; Lai JE; Chodosh J
    Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
    Holcombe DJ; Lee GA
    Am J Ophthalmol; 2006 Oct; 142(4):568-71. PubMed ID: 17011846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children.
    Rogers DJ; Ojha S; Maurer R; Hartnick CJ
    JAMA Otolaryngol Head Neck Surg; 2013 May; 139(5):496-501. PubMed ID: 23681032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical chemotherapy for ocular surface squamous neoplasia: current status.
    Sepulveda R; Pe'er J; Midena E; Seregard S; Dua HS; Singh AD
    Br J Ophthalmol; 2010 May; 94(5):532-5. PubMed ID: 19776089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response.
    Kaliki S; Bejjanki KM; Desai A; Mohamed A
    Semin Ophthalmol; 2019; 34(7-8):465-472. PubMed ID: 31370766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
    Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
    Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
    Zaki AA; Farid SF
    Cornea; 2009 Oct; 28(9):986-8. PubMed ID: 19724215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular surface squamous neoplasia: a standard of care survey.
    Stone DU; Butt AL; Chodosh J
    Cornea; 2005 Apr; 24(3):297-300. PubMed ID: 15778602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience.
    Maturo S; Hartnick CJ
    Arch Otolaryngol Head Neck Surg; 2010 Jun; 136(6):561-5. PubMed ID: 20566906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study.
    Parrozzani R; Lazzarini D; Alemany-Rubio E; Urban F; Midena E
    Br J Ophthalmol; 2011 Mar; 95(3):355-9. PubMed ID: 20693564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical Bevacizumab for the Treatment of Ocular Surface Squamous Neoplasia.
    Asena L; Dursun Altınörs D
    J Ocul Pharmacol Ther; 2015 Oct; 31(8):487-90. PubMed ID: 26114378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in in vivo confocal microscopic findings of ocular surface squamous neoplasia during treatment with topical interferon alfa-2b.
    Zarei-Ghanavati M; Mousavi E; Nabavi A; Latifi G; Mehrjardi HZ; Mohebbi M; Ghassemi H; Mirzaie F; Zare MA
    Ocul Surf; 2018 Apr; 16(2):235-241. PubMed ID: 29306088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia.
    Chen C; Louis D; Dodd T; Muecke J
    Br J Ophthalmol; 2004 Jan; 88(1):17-8. PubMed ID: 14693762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results.
    Enkvetchakul O; Thanathanee O; Rangsin R; Lekhanont K; Suwan-Apichon O
    Cornea; 2011 Nov; 30(11):1213-8. PubMed ID: 21915047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intralesional bevacizumab administration in primary pterygium: a quantitative analysis.
    Sarac O; Demirel S; Oltulu R
    Eye Contact Lens; 2014 Jan; 40(1):46-50. PubMed ID: 24335454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined excision and intralesional bevacizumab for sebaceous carcinoma of the eyelid in an Amur tiger (Panthera tigris altaica).
    Edelmann ML; Utter ML; Klein LV; Wotman KL
    Vet Ophthalmol; 2013 May; 16(3):219-24. PubMed ID: 22857265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.